Propel Bio Partners, a Los Angeles-based venture capital firm that champions healthcare and life sciences innovation, is making waves with a new addition to its leadership team.
The firm has welcomed healthcare technology veteran Laurie Heilmann as its newest Venture Partner, signaling a stronger commitment to guiding startups from early-stage development to successful growth and exits.
Laurie Heilmann Brings Decades of Expertise
With over 30 years of experience in commercialization and operations, Heilmann is no stranger to scaling healthcare ventures.
She will be supporting Propel Bio’s portfolio companies in areas such as commercial strategy, market expansion, and forging strategic partnerships.
Her deep understanding of the healthcare landscape, combined with her global network, promises to provide companies with invaluable guidance as they navigate complex markets.
A Track Record of Success Across Healthcare Sectors
Heilmann’s career spans startups, scale-ups, and multinational operations in diagnostics, drug development, and medical devices.
She notably led Crown Bioscience through an exit to JSR Life Sciences and has served as a Board Director and executive for multiple life science organizations.
Her leadership extends beyond business strategy—she is recognized for building diverse teams and mentoring the next generation of entrepreneurs.
Global Perspective and Strategic Vision
Her professional footprint covers Asia, Europe, and North America, and she has played a key role in multiple successful IPOs and company exits.
Heilmann’s experience equips her to help Propel Bio’s portfolio navigate both domestic and international challenges, turning innovative ideas into commercially viable solutions.
Propel Bio Partners’ Mission and Growth
Founded in 2022 by Dr. Leen Kawas and Richard Kayne, Propel Bio Partners combines financial investment with hands-on operational support to accelerate healthcare innovation.
The firm focuses on empowering entrepreneurs who are developing breakthrough technologies in life sciences, making Heilmann’s appointment a strategic move to strengthen that mission.
Looking Ahead
With Laurie Heilmann on board, Propel Bio Partners is poised to guide its portfolio companies toward expanded market opportunities and long-term success, solidifying its position as a leading investor in healthcare innovation.
Share on Facebook «||» Share on Twitter «||» Share on Reddit «||» Share on LinkedIn